


[Our Company](#)
[Innovation](#)
[Collaborations](#)
[Products](#)
[Media Center](#)
[Investors](#)


# Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership

May 20, 2016 | General Release | 0 comments

EMERYVILLE, Calif., May 20, 2016 (GLOBE NEWSWIRE) — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation (“CJ”)(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris’s farnesene in existing CJ

**f** s. The arrangement described in the MOU would enable Amyris to utilize CJ’s state of the art manufacturing / while minimizing the capital investment necessary to support projected near- and mid-term demand for product

**t** ions using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ

**g+** lang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several /s for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016.

**in**

very pleased with the innovative approach of CJ CheilJedang, to support quickly ramping up our farnesene / with minimal capital investment and with the collaborative partnership to market some of our products in Asia,” said John Melo, President & CEO of Amyris. “This partnership completes our commercialization strategy by providing us the ability to meet our farnesene demand from our current partners without new investment from Amyris and underpins our expected capacity needs to meet farnesene demand that would require building 3-4 new plants the size of our Brotas facility by 2020. We are also pleased with the opportunity to partner with CJ for sales efforts in Asia and the potential to collaborate on new products that meet the needs of their existing customers.”

“We are excited to partner with Amyris and leverage the world’s leading Industrial Biotechnologies to support the growing bio economy in Asia,” said Hang Duk Roh, Head of CJ CheilJedang BIO.

## Follow Us



## Recent Press Releases

Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership  
May 20, 2016

Biossance™ Announces the Blacklist — 2,000+ Potentially Harmful Cosmetic Ingredients it Refuses to Use while Delivering Products Consumers Love to Use  
May 6, 2016

Amyris to Announce First Quarter Financial Results on Tuesday, May 10, 2016  
April 29, 2016

## About CJ CheilJedang Corporation

CJ CheilJedang, is a Korean-based food, feed, and bioscience company, and a subsidiary of the CJ Group. CJ CheilJedang is a global leader in the area of industrial biotechnology with innovations in fermentation and purification technologies. CJ is a leading producer of fermentation-based products such as feed amino acids, MSG, and nucleotides with global manufacturing and business operations in 6 continents. As a socially responsible company, CJ strives toward practicing carbon-neutral manufacturing operations by utilizing renewable raw materials and developing value-added co-products to minimize waste into the environment.

CJ Bio is a division of CJ CheilJedang and operates world-scale fermentation facilities in the United States, China, Indonesia, Malaysia and Brazil.

## About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at [www.amyris.com](http://www.amyris.com).

## Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expectations regarding the company's ability to establish a definitive agreement following execution of the non-binding MOU with CJ, future demand for Amyris products, successful scale-up of manufacturing at CJ facilities and the potential for the two companies to engage in joint product sales and new product development) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including, among other things, risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-Q filed on May 10, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris is a registered trademark of Amyris, Inc. All other trademarks are the property of their respective owners.

**Contact:**

Peter DeNardo

Director, Investor Relations and Corporate Communications

Amyris, Inc.

+1 (510) 740-7481

[investor@amyris.com](mailto:investor@amyris.com)[pr@amyris.com](mailto:pr@amyris.com)**Recent Blog Posts**

- Amyris Named Gold 2016 Edison Award Winner — One of Highest Accolades for Innovation in Business  
May 12, 2016
- Amyris Named #1 Hottest Company in Advanced Bioeconomy  
February 18, 2016
- Biotech Development Just Got Easier for Specialty Chemical, Fragrance Ingredient and

**Recent News Releases**

- Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership  
May 20, 2016
- Biossance™ Announces the Blacklist — 2,000+ Potentially Harmful Cosmetic Ingredients it Refuses to Use while Delivering Products Consumers Love to Use  
May 6, 2016

**Recent Tweets****Amyris @Amyris**

Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership - Supports Farnesene Demand [bit.ly/271ktw4](https://bit.ly/271ktw4)

17:14, Fri

Reply Retweet  
Favorite

**Amyris @Amyris**

Cosmetics Companies  
January 21, 2016

- Amyris to Announce First Quarter Financial Results on Tuesday, May 10, 2016 April 29, 2016



Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth; Reduction in Operating Expenses [bit.ly/1rSpSjd](http://bit.ly/1rSpSjd)

10 May

Reply Retweet

Favorite

[Our Company](#) [Innovation](#) [Collaborations](#) [Products](#) [Media Center](#) [Investors](#)

[Contact Us](#) [Careers](#) [Privacy Policy](#)  
Copyright © 2016 All Rights Reserved.

